What type of receptor does Tirofiban target?

Tirofiban targets the GP IIb/IIIa receptor, which is a glycoprotein found on the surface of platelets. This receptor plays a crucial role in platelet aggregation, particularly in the final common pathway of the coagulation cascade. By blocking the GP IIb/IIIa receptor, Tirofiban prevents fibrinogen from binding to activated platelets, thereby inhibiting platelet aggregation and reducing the risk of thrombus (blood clot) formation.

This mechanism is particularly important in treating acute coronary syndromes and during percutaneous coronary interventions, as it directly reduces the ability of platelets to clump together and form clots that can obstruct blood flow.

Other choices refer to different biological targets; for instance, PAR 1 is involved in platelet activation and thrombin signaling, while PDE3 is an enzyme that breaks down cyclic AMP in platelets, and CYP3A4 is an enzyme involved in drug metabolism. However, Tirofiban's primary action is specifically related to the GP IIb/IIIa receptor, making this the correct choice.